Book a Meeting

BetterBet™ Anti-CD19, a Half-Life Extended Antibody (CAT#: AES-0622-ZP1032) Datasheet

Target
CD19
Description
Creative Biolabs enhances the binding ability of the antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the antibody. The half-life of traditional antibodies is about 3 weeks, and the half-life of the modified antibodies can be increased to more than 50 days in the upper part, which theoretically can greatly reduce the frequency of dosing.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology

Cooperation Seeking

CD19
Official Name
CD19 molecule
Background
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

The Fc of the antibody is engineered to enhance the binding ability of the antibody to FcRn, thereby increasing the half-life of the antibody

Related Products

Highly Galactosylated Anti-CD19 Taplitumomab, a Biobetter Antibody (CAT#: BioBet-GA-100ZP)
Highly Galactosylated Anti-CD19 denintuzumab mafodotin, a Biobetter Antibody (CAT#: BioBet-GA-107ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody, a biobetter (CAT#: BioBet-CB-010LX)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ100] (CAT#: BioBet-100ZP)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ101] (CAT#: BioBet-101ZP)
BetterBet™ Anti-CD19 Recycling Antibody (CAT#: AES-0622-ZP48)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ104] (CAT#: BioBet-104ZP)
Non-Fucosylated Anti-Human CD19 (4G7) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1693ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany